Research programme: cancer immunotherapeutics - Manhattan Biosolutions
Latest Information Update: 28 Jul 2022
At a glance
- Originator Manhattan BioSolutions
- Class Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for research development in Cancer in USA
- 21 Jun 2018 Early research in Cancer in USA (unspecified route) before June 2018